Successful Treatment of Steroid‐Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report

Eosinophilic pneumonia (EP) often requires long-term steroid treatment, which has adverse effects. We report the case of an 83-year-old male with minimal-change nephrotic syndrome, refractory asthma and steroid-induced diabetes who developed a severe steroid-dependent EP relapse during steroid tapering. Considering his age, comorbidities and steroid dependency, treatment with benralizumab, an anti-interleukin-5 receptor antibody, was initiated. Benralizumab rapidly depleted eosinophils, leading to significant clinical and radiological improvements, allowing successful sustained tapering of prednisolone to 5 mg daily, and improving diabetes control without EP relapse. Benralizumab provides effective steroid-sparing therapy for steroid-dependent EP, particularly in complex patients.

Authors

Institutions

Publication Details

Journal
Respirology Case Reports
Published
2025-11-01
DOI
https://doi.org/10.1002/rcr2.70417
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Successful Treatment of Steroid‐Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report

Tomoyoshi Inoue, Keisuke Shiraha, Yuki Takigawa, Mayu Goda et al.
Respirology Case Reports
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

Successful Treatment of Steroid‐Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report

Tomoyoshi Inoue, Keisuke Shiraha, Yuki Takigawa, Mayu Goda, Shoichiro Matsumoto, Keiichi Fujiwara, Kenichiro Kudo, Ken Sato, Akiko Satô, Hiromi Watanabe, Takuo Shibayama, Takeru Ichikawa, Suzuka Matsuoka
article en

Abstract

Eosinophilic pneumonia (EP) often requires long-term steroid treatment, which has adverse effects. We report the case of an 83-year-old male with minimal-change nephrotic syndrome, refractory asthma and steroid-induced diabetes who developed a severe steroid-dependent EP relapse during steroid tapering. Considering his age, comorbidities and steroid dependency, treatment with benralizumab, an anti-interleukin-5 receptor antibody, was initiated. Benralizumab rapidly depleted eosinophils, leading to significant clinical and radiological improvements, allowing successful sustained tapering of prednisolone to 5 mg daily, and improving diabetes control without EP relapse. Benralizumab provides effective steroid-sparing therapy for steroid-dependent EP, particularly in complex patients.

Respirology Case ReportsVol. 13(11)
Okayama Medical Center (JP)
Openalex Percentile: Top 49%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.